Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

MLA

Uwe Kordes, et al. “Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice.” Blood, vol. 132, Nov. 2018, p. 855. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........63f7bed3c1386b43ebf965d1e6e2bac0&authtype=sso&custid=ns315887.

APA

Uwe Kordes, Isabelle Thuret, Ersi Voskaridou, Lena Oevermann, Frédéric Galactéros, Malika Benkerrou, Dominique Steschenko, & Corinne Armari-Alla. (2018). Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice. Blood, 132, 855.

Chicago

Uwe Kordes, Isabelle Thuret, Ersi Voskaridou, Lena Oevermann, Frédéric Galactéros, Malika Benkerrou, Dominique Steschenko, and Corinne Armari-Alla. 2018. “Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice.” Blood 132 (November): 855. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........63f7bed3c1386b43ebf965d1e6e2bac0&authtype=sso&custid=ns315887.